Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma

By afschroeder • August 15, 2025

Meyer T, Finn RS, Borad M, Mahipal A, Edeline J, Houot R, Hausner PF, Hollebecque A, Goyal L, Frigault M, Jeffry Evans TR, Wong KM, Tan BR, Mitry E, Sarker D, Feun L, El-Rayes B, Thistlethwaite F, Kaseb A, Alese O, Jin Z, Cirillo C, Bruix J, Roddie C, Noto P, Fayngerts S, Cristiani S, Sampson J, Bai J, Isabelle M, Broad R, Sun A, Norry E, Sangro B. Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma. J Hepatol. 2025 Aug 12:S0168-8278(25)02404-3. doi: 10.1016/j.jhep.2025.07.033. Epub ahead of print. PMID: 40812667.

Tags: Adoptive T-cell therapy, alpha-fetoprotein, Hematology/Oncology, Hepatocellular carcinoma, immunotherapy, Publications, T-cell receptor T-cell therapy

Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study

Cluzeau T, Borate U, McMahon C, Fenaux P, Heiblig M, Peterlin P, Ball B, Chantepie S, Eghtedar A, Kambhampati S, Solh M, Torregrosa-Diaz J, Braun[...]

Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles Safety-Net Health System: Tyrosine Kinase Inhibitor Treatment Patterns and Outcomes From 2015 to 2024

Zheng D, Nold T, Ramakrishnan N, Kim K, Tomassetti S. Real-World Management of Chronic Myelogenous Leukemia in an Underserved Patient Cohort at a Los Angeles[...]

Evolution and heterogeneity of lethal metastatic bladder cancer subtypes

Itagi P, Schuster SL, Arora S, Persse TW, Waters JA, Yang M, Min A, Chandra P, Adil M, Galipeau PC, Rudoy D, Kreitman AS, Lin[...]